Outpatient therapeutic nuclear oncology

Annals of Nuclear Medicine

Volumn 26, Issue 4, 2012, Pages 289-297

  Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Personalised dosimetry; Radiation protection; Radionuclide cancer treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BOMBESIN DERIVATIVE; CD20 ANTIBODY; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; HOLMIUM 166; INDIUM 111; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; KETOCONAZOLE; LEXIDRONAM SAMARIUM SM 153; LIPIODOL RE 188; LUTETIUM 177; META IODO BENZYL GUANIDINE I 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 LU 177; OCTREOTATE LU 177; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; RITUXIMAB; RITUXIMAB I 131; RITUXIMAB LU 177; SAMARIUM 153; TETRAAZACYCLODODECANE TETRAMETHYLENE PHOSPHATE HO 166; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

BONE METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; GAMMA RADIATION; HUMAN; LIVER CELL CARCINOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MEDICINE; ONCOLOGY; OUTPATIENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID CARCINOMA;

AMBULATORY CARE; HUMANS; NEOPLASMS; NUCLEAR MEDICINE; RADIOTHERAPY;

EID: 84862693682     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0566-z     Document Type: Review

References (70)

1. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54-8. (Pubitemid 47026818)
2. Council of the European Union. Council directive 97/43/EURATOM on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure. Off J Eur Communities. 1997;180:0022-7.
3. 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50: 1518-24.
4. Turner JH. Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Curr Pharm Des. 2009;15:966-82.
5. ICRP. Release of patients after therapy with unsealed radionuclides. ICRP publication 94. Ann ICRP. 2004;34(2).
6. IAEA. Release of patients after radionuclide therapy. Vienna: International Atomic Energy Agency; 2009.
7. Hoefnagel CA, Clarke SEM, Fischer M, et al. Radionuclide therapy practice and facilities in Europe. Eur J Nucl Med. 1999;26:277-82. (Pubitemid 29139860)
8. Harbert JC, Wells N. Radiation exposure to the families of radioactive patients. J Nucl Med. 1974;15:887-8.
9. Jacobson AP, Plato A, Toeroek D. Contamination of the home environment by patients treated with iodine-131: initial results. Am J Public Health. 1978;68:225-30. (Pubitemid 8312379)
10. 131I) therapy for thyroid carcinoma. JAMA. 2000;283:2272-4. (Pubitemid 30246779)
11. Willegagion J, Sapienza M, Ono C, et al. Outpatient therapy of thyroid cancer: a safe nuclear medicine procedure. Clin Nucl Med. 2011;36:440-5.
12. Gabriel S, Farman-Ara B, Bourrelly M, et al. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure. Nucl Med Commun. 2011;32:829-33.
13. Dauer LT, Zanzonico P, Tuttle RM, et al. The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi Power Facility: technical, radiologic and response perspectives. J Nucl Med. 2011;52:1423-32.
14. Australian Radiation Protection and Nuclear Safety Agency. Discharge of patients undergoing treatment with radioactive substances. Radiation protection series no. 4. ARPANSA; 2002.
15. Nuclear Regulatory Commission. Criteria for the release of individual administered radioactive materials, 10 CFR part 20 and 35: 62 FR 4120. Washington, DC: USNRC; 1997.
16. De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2011 [Epub ahead of print].
17. 131I-anti CD 20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a non-myeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharm. 2003;18:513-24. (Pubitemid 37082370)
18. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132:838-47.
19. Higashi T, Nishii R, Yamada S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683-9.
20. Pant GS, Sharma SK, Bal CS, et al. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131-I. Radiat Prot Dosimetry. 2006;118:22-7. (Pubitemid 43786724)
21. 131I therapy. J Nucl Med. 2011;5:681-2.
22. 131I therapy: patient release criteria. 30 June 2010.
23. IAEA Appendix I Safety Reports Series #63. IAEA; 2009.
24. Kinuya S. A nuclear power plant accident in Fukushima: what should we do? Ann Nucl Med. 2011. doi:10.1007/s12149-011-0555-2.
25. 131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2011. doi:10.1007/s12149-011-0553- 4.
26. 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623-30. (Pubitemid 47067049)
27. Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934-40.
28. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of Samarium-153 ethylenediaminetetramethylene phosphonate for disseminated skeletal metastases. J Clin Oncol. 1989;17:1926-31. (Pubitemid 20014342)
29. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose Samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27:1084-6.
30. Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15:784-95. (Pubitemid 20047229)
31. Sinzinger H, Palumbo B, Granegger S. Repeated low-dose Sm-153 EDTMP therapy using the Vienna protocol is effective in pain palliation and lesion regression. J Nucl Med. 2008;49(Suppl):369.
32. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bonetargeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with new, high-energy radiopharmaceutical Rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21:2869-75. (Pubitemid 46621835)
33. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010;40:89-104.
34. 188Re- labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun. 2006;27:223-9. (Pubitemid 44391809)
35. Bayouth JE, Macey DJ, Kasi LP, et al. Pharmacokinetics, dosimetry and toxicity of Holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995;36:730-7.
36. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term followup of the University of Michigan experience. Blood. 2000;96:1259-66. (Pubitemid 30658452)
37. US Nuclear Regulatory Commission. Release of patients administered radioactive materials. Washington, DC: US Nuclear Regulatory Commission; 1997 (Regulatory Guide 8.39, 1997).
38. 131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001;42:907-15. (Pubitemid 32537438)
39. Rutar FJ, Augustine SC, Kaminski MS, et al. Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma. 2001;2:164-72. (Pubitemid 34092722)
40. Calais PJ, Turner JH. Outpatient iodine-131-rituximab radioimmunotherapy of non-Hodgkin lymphoma: a study in safety. Clin Nucl Med. 2011 (in press).
41. 131I-rituximab in routine clinical practice: 10 year single-institution experience of 142 consecutive patients. Blood. 2011;117:45-52.
42. McQuillan AD, Macdonald WBG, Turner JH. Phase II study firstline Iodine-131-rituximab radioimmunotherapy of follicular non-Hodgkin lymphoma with Fluorine-18 FDG-PET-CT response end point. Blood 2011; (in press).
43. 177Lu-D-R): a phase I/II study in 30 patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas. In: 50th ASH Annual Meeting and Exposition; 2008.
44. 3] octreotate: toxicity, efficacy and survival. J Clin Oncol. 2008;26:2124-30.
45. Fitschen J, Knoop BO, Behrendt R et al. Äußere Strahlenexposition und effektive Halbwertszeit bei therpie mit Lu-177-Dota-Tate. Z Med Phys. 2011. doi:10.1016/j.zemedi.2011.05.001.
46. 3-octreotate radiopeptide therapy of neuroendocrine tumours with personalized dosimetry and so to BED. Eur J Nucl Med Mol Imaging 2011 (under review).
47. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302-11.
48. 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumours. Acta Oncol. ESMO; 2011 (Abst).
49. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13:769-75.
50. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroblastoma tumors. Semin Nucl Med. 2010;40:153-63.
51. Sudbrock F, Boldt F, Kobe C, et al. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Nuklearmedizin. 2009;48:17-25.
52. Kwekkeboom DJ, de Herder WW, Casper HJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78-88.
53. 131Iodine lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging. 2005;53:348-55.
54. Chua TC, Chu F, Butler P, et al. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer. 2010;116:4069-77.
55. Sundram F, Chau TCM, Onkhuudai P, et al. Preliminary results of transarterial Rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:250-7. (Pubitemid 38173701)
56. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med. 2011;364:2055-8.
57. 177Lutetium-labeled J591, a monoclonal antibody to prostatespecific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-601. (Pubitemid 46224061)
58. 177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol. In: Proceedings of Asco Annual Meeting, part 1, vol 24, p. 18S; 2006.
59. 177Lu radiolabeled monoclonal antibody HuJ591 (177-Lu-J591) and ketoconazole in patients with prostate cancer. Clinical Trials.gov: NCT00859781; 2009.
60. Olafsen T, Ho DT, Lipman AA et al. Highly-specific small animal PET imaging of prostate specific membrane antigen (PSMA) xenografts by an engineered humanized antibody fragment (minibody). In: ASCO. http://www.wmicmeeting.org/ 2010/Abstracts.
61. Schroeder RPJ, Müller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37: 1386-96.
62. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017-24.
63. 99mTc] Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med. 2003;30:247-58. (Pubitemid 36686844)
64. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPrpositive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
65. 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging. 2009;36:1425-33.
66. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429-35.
67. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010;40:167-81.
68. Sharkey RM, Rossi EA, McBride WJ, et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190-203.
69. Brans B, Van Den Eynde F, Audenaert K, et al. Depression and anxiety during isolation and radionuclide therapy. Nucl Med Commun. 2003;24:881-6.
70. The World Association of Radionuclide & Molecular Therapy (WARMTH). http://www.warmolth.org.